These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 23621175)

  • 1. Omalizumab for treatment of allergic rhinitis.
    Vashisht P; Casale T
    Expert Opin Biol Ther; 2013 Jun; 13(6):933-45. PubMed ID: 23621175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-IgE for the treatment of allergic rhinitis--and eventually nasal polyps?
    Verbruggen K; Van Cauwenberge P; Bachert C
    Int Arch Allergy Immunol; 2009; 148(2):87-98. PubMed ID: 18799888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
    Holgate ST; Djukanović R; Casale T; Bousquet J
    Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etiopathogenesis and management of perennial allergic rhinitis: a state-of-the-art review.
    Bush RK
    Treat Respir Med; 2004; 3(1):45-57. PubMed ID: 15174893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis.
    Corren J; Diaz-Sanchez D; Saxon A; Deniz Y; Reimann J; Sinclair D; Davancaze T; Adelman D
    Ann Allergy Asthma Immunol; 2004 Sep; 93(3):243-8. PubMed ID: 15478383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-IgE--emerging opportunities for Omalizumab.
    Babu KS; Polosa R; Morjaria JB
    Expert Opin Biol Ther; 2013 May; 13(5):765-77. PubMed ID: 23517576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN).
    Bousquet J; van Cauwenberge P; Aït Khaled N; Bachert C; Baena-Cagnani CE; Bouchard J; Bunnag C; Canonica GW; Carlsen KH; Chen YZ; Cruz AA; Custovic A; Demoly P; Dubakiene R; Durham S; Fokkens W; Howarth P; Kemp J; Kowalski ML; Kvedariene V; Lipworth B; Lockey R; Lund V; Mavale-Manuel S; Meltzer EO; Mullol J; Naclerio R; Nekam K; Ohta K; Papadopoulos N; Passalacqua G; Pawankar R; Popov T; Potter P; Price D; Scadding G; Simons FE; Spicak V; Valovirta E; Wang DY; Yawn B; Yusuf O;
    Allergy; 2006 Sep; 61(9):1086-96. PubMed ID: 16918512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.
    Casale TB; Condemi J; LaForce C; Nayak A; Rowe M; Watrous M; McAlary M; Fowler-Taylor A; Racine A; Gupta N; Fick R; Della Cioppa G;
    JAMA; 2001 Dec; 286(23):2956-67. PubMed ID: 11743836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab. A review of the new treatment of allergic asthma and seasonal allergic rhinitis.
    Félix Toledo R; Negro Alvarez JM; Miralles López JC
    Allergol Immunopathol (Madr); 2002; 30(2):94-9. PubMed ID: 11958741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
    BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Omalizumab, recombinant humanized monoclonal antibody anti-IgE -- new fields of studies on the therapeutic indications].
    Kupryś-Lipińska I; Kuna P
    Pneumonol Alergol Pol; 2009; 77(1):43-51. PubMed ID: 19308909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with monoclonal antibodies in allergic mediated disease: seasonal allergic rhinitis.
    Casale TB
    J Allergy Clin Immunol; 2001 Aug; 108(2 Suppl):S84-8. PubMed ID: 11498678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab: an effective anti-IgE treatment for allergic asthma and rhinitis.
    Casale TB;
    Drugs Today (Barc); 2004 Apr; 40(4):367-76. PubMed ID: 15190389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of immunmodulators in allergen-specific immunotherapy.
    Kopp MV
    Allergy; 2011 Jun; 66(6):792-7. PubMed ID: 21332502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy for allergic rhinitis.
    Melvin TA; Patel AA
    Otolaryngol Clin North Am; 2011 Jun; 44(3):727-39, x. PubMed ID: 21621057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of allergic rhinitis and other immunoglobulin E-mediated diseases with anti-immunoglobulin E antibody.
    Berger WE
    Allergy Asthma Proc; 2006; 27(2 Suppl 1):S29-32. PubMed ID: 16722329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-IgE treatment in allergic rhinitis.
    Bayar Muluk N; Bafaqeeh SA; Cingi C
    Int J Pediatr Otorhinolaryngol; 2019 Dec; 127():109674. PubMed ID: 31526939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab : other indications and unanswered questions.
    Mankad VS; Burks AW
    Clin Rev Allergy Immunol; 2005 Aug; 29(1):17-30. PubMed ID: 16222081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis.
    Kim DH; Park KY; Kim BJ; Kim MN; Mun SK
    Clin Exp Dermatol; 2013 Jul; 38(5):496-500. PubMed ID: 23083013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.